Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mammary Neoplasms, Experimental | 5 | 2024 | 498 | 0.820 |
Why?
|
Losartan | 3 | 2021 | 259 | 0.790 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 3 | 2021 | 439 | 0.720 |
Why?
|
Radiation Tolerance | 5 | 2017 | 476 | 0.680 |
Why?
|
Neoplasm Transplantation | 11 | 2014 | 2012 | 0.530 |
Why?
|
Receptors, CXCR4 | 5 | 2019 | 728 | 0.450 |
Why?
|
Phenylurea Compounds | 4 | 2020 | 523 | 0.450 |
Why?
|
Carcinoma, Hepatocellular | 7 | 2022 | 2269 | 0.440 |
Why?
|
Glioblastoma | 5 | 2021 | 3471 | 0.410 |
Why?
|
Rodent Diseases | 1 | 2011 | 52 | 0.390 |
Why?
|
Mice, SCID | 6 | 2016 | 2617 | 0.370 |
Why?
|
Niacinamide | 3 | 2017 | 410 | 0.330 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 4 | 2019 | 544 | 0.330 |
Why?
|
Liver Neoplasms | 7 | 2022 | 4271 | 0.320 |
Why?
|
Mice | 52 | 2024 | 80543 | 0.320 |
Why?
|
Neoplasms, Experimental | 3 | 2019 | 1228 | 0.320 |
Why?
|
Tumor Cells, Cultured | 10 | 2021 | 6137 | 0.320 |
Why?
|
Transplantation, Heterologous | 10 | 2015 | 2368 | 0.320 |
Why?
|
Neovascularization, Pathologic | 6 | 2019 | 2625 | 0.300 |
Why?
|
Liver Neoplasms, Experimental | 2 | 2021 | 188 | 0.300 |
Why?
|
Tumor Microenvironment | 9 | 2024 | 3755 | 0.280 |
Why?
|
Mice, Nude | 13 | 2019 | 3582 | 0.270 |
Why?
|
Receptor, erbB-2 | 3 | 2024 | 2483 | 0.270 |
Why?
|
Animals | 60 | 2024 | 166802 | 0.270 |
Why?
|
Cell Line, Tumor | 17 | 2024 | 16736 | 0.260 |
Why?
|
Stress, Mechanical | 3 | 2020 | 1661 | 0.250 |
Why?
|
Immunotherapy | 5 | 2021 | 4601 | 0.250 |
Why?
|
Brain Neoplasms | 5 | 2020 | 8892 | 0.240 |
Why?
|
Whole-Body Irradiation | 2 | 2014 | 422 | 0.230 |
Why?
|
Disulfiram | 1 | 2024 | 63 | 0.230 |
Why?
|
Neurofibromatosis 2 | 2 | 2019 | 385 | 0.230 |
Why?
|
Neuroma, Acoustic | 2 | 2019 | 453 | 0.220 |
Why?
|
Radiotherapy Dosage | 6 | 2023 | 2906 | 0.220 |
Why?
|
Disease Models, Animal | 13 | 2023 | 17958 | 0.220 |
Why?
|
Sarcoma | 5 | 1996 | 1788 | 0.210 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2022 | 3468 | 0.210 |
Why?
|
Breast Neoplasms | 9 | 2024 | 20843 | 0.200 |
Why?
|
MicroRNAs | 1 | 2017 | 3764 | 0.190 |
Why?
|
Copper | 1 | 2024 | 368 | 0.190 |
Why?
|
Glucocorticoid-Induced TNFR-Related Protein | 1 | 2021 | 41 | 0.190 |
Why?
|
Sciatica | 1 | 2021 | 97 | 0.180 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2021 | 5163 | 0.180 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2014 | 548 | 0.180 |
Why?
|
Green Fluorescent Proteins | 1 | 2005 | 2050 | 0.170 |
Why?
|
Chemokine CXCL10 | 1 | 2020 | 315 | 0.170 |
Why?
|
Osteosarcoma | 1 | 2005 | 888 | 0.170 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2023 | 3029 | 0.170 |
Why?
|
Cerebellopontine Angle | 1 | 2019 | 52 | 0.160 |
Why?
|
Angiogenesis Inhibitors | 3 | 2022 | 2036 | 0.160 |
Why?
|
Cholangiocarcinoma | 1 | 2024 | 545 | 0.160 |
Why?
|
Receptor, Angiotensin, Type 1 | 2 | 2016 | 134 | 0.160 |
Why?
|
Mice, Inbred BALB C | 2 | 2024 | 6112 | 0.160 |
Why?
|
Cisplatin | 1 | 2024 | 1643 | 0.150 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13165 | 0.150 |
Why?
|
Protons | 1 | 2023 | 1120 | 0.150 |
Why?
|
Mice, Inbred C3H | 5 | 2015 | 911 | 0.140 |
Why?
|
Cancer Vaccines | 1 | 2024 | 1048 | 0.140 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2016 | 112 | 0.130 |
Why?
|
Adenocarcinoma | 4 | 2024 | 6306 | 0.130 |
Why?
|
Th1 Cells | 1 | 2021 | 999 | 0.130 |
Why?
|
Receptors, Estrogen | 1 | 2024 | 2181 | 0.130 |
Why?
|
Elasticity | 1 | 2018 | 653 | 0.130 |
Why?
|
Implants, Experimental | 1 | 2016 | 99 | 0.130 |
Why?
|
Nasopharyngeal Neoplasms | 4 | 1991 | 287 | 0.130 |
Why?
|
Lithium | 1 | 2019 | 598 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11586 | 0.130 |
Why?
|
Maytansine | 1 | 2015 | 86 | 0.120 |
Why?
|
Pathology | 1 | 2018 | 263 | 0.120 |
Why?
|
Inflammation Mediators | 2 | 2021 | 1873 | 0.120 |
Why?
|
Indomethacin | 1 | 1995 | 324 | 0.120 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2014 | 112 | 0.120 |
Why?
|
Neoplasms | 5 | 2019 | 21808 | 0.120 |
Why?
|
Liver Cirrhosis | 2 | 2015 | 1892 | 0.120 |
Why?
|
Neutrons | 1 | 2014 | 77 | 0.120 |
Why?
|
Organ Culture Techniques | 1 | 2016 | 795 | 0.110 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4495 | 0.110 |
Why?
|
Minocycline | 1 | 2014 | 169 | 0.110 |
Why?
|
Mesenchymal Stem Cells | 1 | 2024 | 1618 | 0.110 |
Why?
|
Lymphatic Vessels | 1 | 2018 | 354 | 0.110 |
Why?
|
Lymph Nodes | 2 | 2023 | 3474 | 0.110 |
Why?
|
Nasopharyngitis | 2 | 1991 | 10 | 0.110 |
Why?
|
Hyperalgesia | 1 | 2017 | 523 | 0.110 |
Why?
|
Bone Neoplasms | 1 | 2005 | 2511 | 0.110 |
Why?
|
Antineoplastic Agents | 5 | 2017 | 13553 | 0.110 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 1002 | 0.110 |
Why?
|
Spinal Cord | 1 | 2021 | 1804 | 0.110 |
Why?
|
Scattering, Radiation | 1 | 2014 | 490 | 0.100 |
Why?
|
Angiotensins | 1 | 2013 | 144 | 0.100 |
Why?
|
Neoplastic Stem Cells | 2 | 2024 | 1341 | 0.100 |
Why?
|
Cranial Irradiation | 1 | 2014 | 392 | 0.100 |
Why?
|
Chemokine CXCL12 | 1 | 2014 | 453 | 0.100 |
Why?
|
Intestines | 1 | 2021 | 1896 | 0.100 |
Why?
|
Benzimidazoles | 1 | 2017 | 854 | 0.100 |
Why?
|
Hearing Loss | 1 | 2019 | 768 | 0.100 |
Why?
|
Stress, Physiological | 1 | 2019 | 1392 | 0.100 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 693 | 0.090 |
Why?
|
Drug Delivery Systems | 3 | 2019 | 2213 | 0.090 |
Why?
|
Receptors, Chemokine | 1 | 2014 | 651 | 0.090 |
Why?
|
Lymphatic Metastasis | 4 | 2023 | 2924 | 0.090 |
Why?
|
Guanylate Cyclase | 1 | 2011 | 202 | 0.090 |
Why?
|
Bacteria | 1 | 2021 | 2161 | 0.090 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2014 | 590 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5594 | 0.080 |
Why?
|
Female | 28 | 2024 | 386053 | 0.080 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2011 | 508 | 0.080 |
Why?
|
Myeloid Cells | 1 | 2014 | 815 | 0.080 |
Why?
|
Pyridines | 1 | 2020 | 2861 | 0.080 |
Why?
|
Nasopharynx | 1 | 1991 | 391 | 0.080 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2011 | 617 | 0.080 |
Why?
|
Thymus Neoplasms | 1 | 2011 | 273 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10036 | 0.080 |
Why?
|
Lymphokines | 1 | 2011 | 928 | 0.080 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2015 | 872 | 0.070 |
Why?
|
Male | 25 | 2021 | 354881 | 0.070 |
Why?
|
Toll-Like Receptor 4 | 1 | 2011 | 572 | 0.070 |
Why?
|
Mice, Knockout | 6 | 2021 | 14296 | 0.070 |
Why?
|
Random Allocation | 3 | 2017 | 2387 | 0.070 |
Why?
|
Stromal Cells | 4 | 2016 | 1317 | 0.070 |
Why?
|
Pancreatic Neoplasms | 2 | 2016 | 5288 | 0.070 |
Why?
|
Survival Rate | 1 | 2021 | 12746 | 0.070 |
Why?
|
Longevity | 1 | 2014 | 1035 | 0.070 |
Why?
|
Spheroids, Cellular | 2 | 2019 | 329 | 0.070 |
Why?
|
Mice, Inbred C57BL | 6 | 2021 | 21712 | 0.070 |
Why?
|
Neurofibromin 2 | 2 | 2019 | 270 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 1995 | 1149 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7235 | 0.070 |
Why?
|
Mice, Transgenic | 4 | 2021 | 9465 | 0.070 |
Why?
|
Humans | 34 | 2024 | 752341 | 0.060 |
Why?
|
Nasal Mucosa | 1 | 1989 | 411 | 0.060 |
Why?
|
Nanoparticles | 1 | 2017 | 1911 | 0.060 |
Why?
|
Carbon Tetrachloride | 2 | 2015 | 65 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3599 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2017 | 10358 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3502 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 1996 | 2503 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 2 | 1991 | 2821 | 0.060 |
Why?
|
Brain | 4 | 2020 | 26655 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1995 | 4343 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2021 | 1758 | 0.050 |
Why?
|
Sarcoma, Experimental | 1 | 2003 | 119 | 0.050 |
Why?
|
Tibia | 1 | 2008 | 1061 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2020 | 1268 | 0.050 |
Why?
|
Pain | 1 | 2017 | 4988 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6793 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2016 | 3177 | 0.050 |
Why?
|
Tumor Burden | 2 | 2016 | 1875 | 0.040 |
Why?
|
Myocardial Ischemia | 1 | 2011 | 2151 | 0.040 |
Why?
|
Neuroprotective Agents | 2 | 2019 | 956 | 0.040 |
Why?
|
Inflammation | 2 | 2018 | 10690 | 0.040 |
Why?
|
Cell Survival | 3 | 2018 | 5771 | 0.040 |
Why?
|
Nitrosamines | 2 | 1991 | 84 | 0.040 |
Why?
|
Compressive Strength | 1 | 2020 | 157 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2016 | 4274 | 0.040 |
Why?
|
Antibodies | 2 | 2019 | 2411 | 0.040 |
Why?
|
Signal Transduction | 5 | 2016 | 23233 | 0.040 |
Why?
|
Receptors, Progesterone | 1 | 2024 | 1114 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 717 | 0.040 |
Why?
|
Microscopy, Confocal | 1 | 2005 | 1976 | 0.040 |
Why?
|
Photons | 1 | 2023 | 588 | 0.040 |
Why?
|
Injections, Intraventricular | 1 | 2019 | 224 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 427 | 0.040 |
Why?
|
Graft Survival | 1 | 1989 | 3626 | 0.040 |
Why?
|
Specific Pathogen-Free Organisms | 2 | 1995 | 220 | 0.040 |
Why?
|
Hearing Tests | 1 | 2019 | 121 | 0.040 |
Why?
|
Liver | 1 | 2014 | 7426 | 0.040 |
Why?
|
Cognition | 1 | 2014 | 6846 | 0.040 |
Why?
|
Luciferases | 1 | 2019 | 717 | 0.040 |
Why?
|
Pain Threshold | 1 | 2021 | 594 | 0.040 |
Why?
|
Muscle Cells | 1 | 2018 | 194 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4861 | 0.040 |
Why?
|
In Situ Nick-End Labeling | 1 | 2018 | 613 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1820 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2021 | 64245 | 0.030 |
Why?
|
Stereotaxic Techniques | 1 | 2019 | 545 | 0.030 |
Why?
|
Etoposide | 1 | 1998 | 625 | 0.030 |
Why?
|
Transfection | 2 | 2014 | 5780 | 0.030 |
Why?
|
Collagen | 2 | 2016 | 2627 | 0.030 |
Why?
|
Rotarod Performance Test | 1 | 2015 | 63 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 1995 | 5726 | 0.030 |
Why?
|
Sulfotransferases | 1 | 2016 | 149 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 405 | 0.030 |
Why?
|
Apoptosis | 4 | 2015 | 9429 | 0.030 |
Why?
|
Databases, Factual | 1 | 2011 | 7898 | 0.030 |
Why?
|
Dimethylpolysiloxanes | 1 | 2016 | 142 | 0.030 |
Why?
|
Lethal Dose 50 | 1 | 2014 | 73 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2017 | 8157 | 0.030 |
Why?
|
Hearing | 1 | 2019 | 494 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2019 | 1531 | 0.030 |
Why?
|
Indoles | 1 | 2023 | 1815 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7580 | 0.030 |
Why?
|
Radiation-Protective Agents | 1 | 2014 | 88 | 0.030 |
Why?
|
Antibodies, Monoclonal | 3 | 2003 | 9101 | 0.030 |
Why?
|
Hindlimb | 1 | 1996 | 506 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2021 | 1324 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2019 | 2509 | 0.030 |
Why?
|
Immune Tolerance | 1 | 2023 | 2224 | 0.030 |
Why?
|
Perfusion | 1 | 2019 | 1364 | 0.030 |
Why?
|
Cricetinae | 1 | 1998 | 2421 | 0.030 |
Why?
|
Obesity | 1 | 2016 | 12806 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1060 | 0.030 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2014 | 178 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2016 | 8538 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 800 | 0.030 |
Why?
|
Lymphocytes | 1 | 2021 | 2592 | 0.030 |
Why?
|
Cell Line | 3 | 2017 | 15633 | 0.030 |
Why?
|
Cell Movement | 2 | 2016 | 5172 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3124 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2021 | 1854 | 0.030 |
Why?
|
Connective Tissue Growth Factor | 1 | 2013 | 91 | 0.030 |
Why?
|
Muscular Atrophy | 1 | 2015 | 326 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11007 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2015 | 752 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 263 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1439 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 4419 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 3 | 1995 | 4004 | 0.030 |
Why?
|
Microscopy, Electron | 1 | 2015 | 2560 | 0.030 |
Why?
|
Sciatic Nerve | 1 | 2015 | 608 | 0.030 |
Why?
|
Polymers | 1 | 2019 | 1610 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2018 | 18915 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2018 | 1898 | 0.020 |
Why?
|
Edema | 1 | 2015 | 771 | 0.020 |
Why?
|
Oxygen | 1 | 2023 | 4171 | 0.020 |
Why?
|
Endothelin-1 | 1 | 2013 | 301 | 0.020 |
Why?
|
Nitrites | 1 | 2011 | 158 | 0.020 |
Why?
|
Rats | 3 | 2017 | 23562 | 0.020 |
Why?
|
Drug Repositioning | 1 | 2013 | 232 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 4067 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2021 | 2715 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2016 | 996 | 0.020 |
Why?
|
Blood Vessels | 1 | 2016 | 1114 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 2013 | 660 | 0.020 |
Why?
|
Nerve Regeneration | 1 | 2015 | 781 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1809 | 0.020 |
Why?
|
Cell Division | 3 | 2004 | 4445 | 0.020 |
Why?
|
Nitrates | 1 | 2011 | 262 | 0.020 |
Why?
|
Hyaluronic Acid | 1 | 2013 | 473 | 0.020 |
Why?
|
Skin | 1 | 2023 | 4421 | 0.020 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2011 | 306 | 0.020 |
Why?
|
Carcinogens | 1 | 1991 | 448 | 0.020 |
Why?
|
Fibrosis | 1 | 2016 | 2011 | 0.020 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2013 | 607 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 1774 | 0.020 |
Why?
|
Drug Synergism | 1 | 2013 | 1735 | 0.020 |
Why?
|
Cocarcinogenesis | 1 | 1988 | 50 | 0.020 |
Why?
|
Neurogenesis | 1 | 2014 | 845 | 0.020 |
Why?
|
Kinetics | 1 | 1996 | 6352 | 0.020 |
Why?
|
Growth Inhibitors | 1 | 1989 | 376 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5035 | 0.020 |
Why?
|
Mucous Membrane | 1 | 1991 | 654 | 0.020 |
Why?
|
Fluorouracil | 1 | 2013 | 1606 | 0.020 |
Why?
|
Equipment Design | 1 | 2016 | 3510 | 0.020 |
Why?
|
DNA Damage | 1 | 1998 | 2407 | 0.020 |
Why?
|
Biocompatible Materials | 1 | 2016 | 1687 | 0.020 |
Why?
|
Mechanotransduction, Cellular | 1 | 2013 | 528 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2843 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4880 | 0.020 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2011 | 476 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3553 | 0.020 |
Why?
|
Plants, Medicinal | 1 | 1988 | 163 | 0.020 |
Why?
|
Pain Measurement | 1 | 2017 | 3463 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3448 | 0.020 |
Why?
|
Neuroblastoma | 1 | 1995 | 1240 | 0.020 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2011 | 579 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2011 | 2476 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2014 | 9207 | 0.020 |
Why?
|
Fibroblasts | 1 | 2016 | 4056 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 1991 | 794 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 1995 | 6509 | 0.020 |
Why?
|
Benzamides | 1 | 2011 | 1364 | 0.020 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2016 | 1692 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6501 | 0.020 |
Why?
|
Doxorubicin | 1 | 2011 | 2192 | 0.010 |
Why?
|
Body Weight | 1 | 1995 | 4606 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2016 | 3285 | 0.010 |
Why?
|
Carcinoma | 1 | 1995 | 2340 | 0.010 |
Why?
|
Neutrophils | 1 | 2016 | 3724 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3686 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9701 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2011 | 2214 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 2003 | 245 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7294 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 19894 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4474 | 0.010 |
Why?
|
Macrophages | 1 | 2016 | 5693 | 0.010 |
Why?
|
Piperazines | 1 | 2011 | 2486 | 0.010 |
Why?
|
Models, Biological | 1 | 2016 | 9449 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2008 | 1969 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 9355 | 0.010 |
Why?
|
Neurons | 1 | 2019 | 9351 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13402 | 0.010 |
Why?
|
Pyrimidines | 1 | 2011 | 2978 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16439 | 0.010 |
Why?
|
Prospective Studies | 1 | 2023 | 53807 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 12796 | 0.010 |
Why?
|
Echocardiography | 1 | 2011 | 4950 | 0.010 |
Why?
|
Electrocardiography | 1 | 2011 | 6379 | 0.010 |
Why?
|
Time Factors | 2 | 1996 | 39854 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18297 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8422 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17648 | 0.010 |
Why?
|
Chronic Disease | 1 | 1989 | 9158 | 0.010 |
Why?
|
HeLa Cells | 2 | 1990 | 3086 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14586 | 0.010 |
Why?
|
Carcinogenicity Tests | 1 | 1989 | 38 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2011 | 11830 | 0.010 |
Why?
|
Spleen | 1 | 1989 | 2274 | 0.000 |
Why?
|
Adolescent | 1 | 1989 | 86765 | 0.000 |
Why?
|
Middle Aged | 1 | 1989 | 217019 | 0.000 |
Why?
|
Adult | 1 | 1989 | 216913 | 0.000 |
Why?
|